Steve Gillis, Ph.D.
Dr. Steven Gillis is a managing director with ARCH Venture Partners, joining the firm in 2005. Dr. Gillis is focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. He is a director of Accelerator, Allozyne, Variation Biotechnologies, Surface Logix, PhaseRx, Pulmatrix and Qwell Pharmaceuticals. He serves as director and chairman of VentiRx Pharmaceuticals, Spaltudaq and VLST. As a former director and chairman of Trubion Pharmaceuticals (TRBN), he led its acquisition by Emergent BioSolutions in early 2010.
Dr. Gillis was a founder and director of Corixa Corp. and served as the company’s chief executive officer from its inception and as its chairman from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, he served as Immunex’s director of research and development, chief scientific officer, and as chief executive officer of Immunex’s R&D subsidiary. Dr. Gillis was interim chief executive officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a member of the board until 1997. Amgen, Inc. acquired Immunex in 2002.
Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein), as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received a B.A. from Williams College and a Ph.D. from Dartmouth College.
Kristina Burow is a Managing Director with ARCH Venture Partners and is focused on the creation and development of biotechnology, pharmaceutical and agbiotechnology companies. Since joining ARCH in 2002 Ms. Burow has played a significant role in the creation and development of a number of companies. Ms. Burow is a Director of Vividion Therapeutics, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals, Metacrine, Scholar Rock, Unity Biotechnology, AgBiome, AgTech Accelerator and Vir Biotechnology. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene). Ms. Burow has participated in a number of other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH – acquired by Allergan), Ikaria (acquired by Madison Dearborn) and was a co-founder and board member of Sapphire Energy. Prior to joining ARCH Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spin-outs from GNF. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.
Michael R. Hayden MB, ChB, PhD, FRCP (C), FRSC, C.M., O.B.C.
Dr. Michael Hayden joined Teva as president of Global R&D and chief scientific officer in May 2012. He is also the Killam Professor of Medical Genetics at the University of British Columbia and Canada Research Chair in Human Genetics and Molecular Medicine. In addition, he is the founder and senior scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.
Prior to joining Teva, Dr. Hayden founded three biotechnology companies – NeuroVir, Aspreva Pharmaceuticals, and Xenon Pharmaceuticals Inc. – and served as chief scientific officer of Xenon from 2000 to 2012. He also served as a director of Med Biogene Inc. (2010 – 2011).
Dr. Hayden is the recipient of numerous honors and awards, including the Canada Gairdner Wightman Award in 2011, the Order of Canada Award (2010), which is the highest honor that Canada can give its citizens for exceptional achievement, and the Distinguished Scientist Award of the Canadian Society of Clinical Investigation (1998). In 2008 Dr. Hayden was named Canada’s Health Researcher of the Year.
Dr. Hayden received his MB ChB degree in Medicine in 1975, PhD degree in Genetics in 1979, and DCH Diploma in Child Health in 1979, all from the University of Cape Town. He received his American Board Certification in both internal medicine and clinical genetics from Harvard Medical School in 1982 and an FRCPC in internal medicine from the University of British Columbia in 1984.
Robert Kamen, Ph.D.
Dr. Robert Kamen is a consultant to the biotech and pharmaceutical industry. Most recently, he was president of Abbott Bioresearch Center, Abbott Laboratories’ immunology drug discovery and biologics production unit in Worcester, Massachusetts, and a member of the Abbott Pharmaceuticals Executive Management Committee. During Dr. Kamen’s leadership at BASF/Abbott, the company established the technology platform for Humira™ (adalimumab), the first fully human antibody to achieve marketing approval in the U.S. (and Europe). Currently marketed for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and psoriasis, Humira was the most rapidly growing U.S. biological drug in 2007 and 2008. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, where he serves as chairman. In addition, Dr. Kamen is a member of several other biopharmaceutical company boards.
Dr. Kamen has an undergraduate degree in biophysics from Amherst College and a Ph.D. in biochemistry and molecular biology from Harvard University.
Nina Kjellson joined Cannan’s healthcare team as General Partner in 2015 from InterWest Partners where she has been investing in healthcare start-ups since 2002. She focuses primarily on investments in biopharmaceuticals and digital health. Nina is co-founder and co-chair of ConsumerMed.org, a forum to address the convergence of health care and consumer innovation and serves as a mentor to Blueprint Health, a digital health incubator and Springboard Life Sciences, an accelerator for healthcare companies driven by women entrepreneurs. Investment themes include innovative therapeutics for serious and underserved conditions, IT-enabled transformation of healthcare delivery and patient/consumer engagement.
Current investments include Cidara (CDTX), Eiger Biopharmaceuticals, Lycera, Ocera (OCRX), Paratek (PRTK), and WellTok.
Previous investments include Labrys Biologics (acquired by Teva), Alt12 (acquired by Honest Company), Trius Therapeutics (TSRX; acquired by Cubist), CNS Therapeutics (acquired by Covidien), NovaCardia (acquired by Merck), and Aspreva (ASPV; acquired by Galenica) Prior to InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina received a B.A. in human biology from Stanford University (1997).
She serves on the California Leadership Council for the Nature Conservancy and has been nominated to join the board of the California Family Health Council.
Timothy M. Mayleben
Mr. Tim Mayleben is chief executive officer, president, and a member of the board of directors at Esperion Therapeutics. Previously he was president, CEO and a member of the board of directors at Aastrom Biosciences and an advisor to life science and healthcare companies through his advisory and investment firm, ElMa Advisors. He has also been president, chief operating officer and a director of NightHawk Radiology Holdings, Inc. Mr. Mayleben also served as chief operating officer of the original Esperion Therapeutics, where he led the raising of more than $200 million in venture capital and institutional equity funding and later negotiated the acquisition of Esperion by Pfizer in December 2003 for $1.3 billion. Mr. Mayleben is on the advisory board of the Wolverine Venture Fund and serves as a director for several private life science companies.
He holds an M.B.A. with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.A. in business administration from the University of Michigan Ross Business School.
Paul Sekhri joined Lycera as President and CEO in February 2015. Prior to this he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Lt. Prior to joining Teva he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004-2009 Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc.
Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic areas upon which the company would focus. His first role at Novartis was as Global Head, Early Commercial Development – a department he established to ensure the differential competitive advantage of Novartis’ pipeline.
Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in Zoology.
Mr. Sekhri has been a Director on sixteen private and public company Boards, and is currently a member of the Board of Directors of Veeva System, Pharming N.V., Enumeral Biomedical, and was a recent board observer at IMS Health.
Additionally, he is on the Board of Directors of the non-profit Cancer Research Institute, the BioExec Institute, Inc., the Industry Advisory Board of the Michael J. Fox Foundation, the TB Alliance, the Tectonic Theatre Project, and was recently elected to the Board of Directors of Young Concert Artists, Inc. Mr. Sekhri also served as a Member of the Board of Trustees of Carnegie Hall from 2010-2012, where he is now an active member of their Patrons Council.
Nicholas J. Simon, MBA
Nicholas Simon has served as managing director of Clarus Ventures since the firm’s inception in 2005. Previously, Mr. Simon was general partner at MPM Capital. He has over 20 years of operating and investment experience in the biopharmaceutical industry, including at Genentech from 1989 to 2000, where he was vice president of business and corporate development.
Mr. Simon also represents Clarus Ventures on the Board of Directors of Gritstone Oncology, Nuvelution Pharma, Inc. and Sientra, where he serves as Lead Director. In addition, he is a member of the Foundation Board at the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco.
Mr. Simon received his BS degree in microbiology from the University of Maryland and MBA from Loyola University.
Mary Lincoln Campbell
Mary Lincoln Campbell, Managing Director and Founder of EDF Ventures, has been an active investor both in healthcare and technology companies. Currently, Mary is a board member or board observer for: Cerenis Therapeutics and Lycera (pharmaceuticals); IntelePeer (telecommunications); ValenTx (medical devices); Arxan (software); and Accio Energy (wind-energy).
Mary led several of the firm’s most successful transactions including HandyLab, a developer of molecular diagnostic assays and automation platforms, sold to Becton Dickinson & Company; Sircon, a provider of automation solutions for the insurance industry, sold to Vertafore, the nation’s number one insurance software provider; and Greenplum, a database clustering software for business intelligence and data warehousing, sold to EMC Corporation, the world’s leading provider of information infrastructure solutions.
She is active with The Stephen M. Ross School of Business at The University of Michigan and serves as an advisor to the Zell Lurie Institute for Entrepreneurial Studies, as well as its student-run venture activity, the Wolverine Venture Fund. She serves on the advisory board of The Charles F. Dolan School of Business at Fairfield University. Mary is past president of the Michigan Venture Capital Association, the State’s premier public policy advocate for the venture capital industry.
Mary received her MBA and BA in English from The University of Michigan and a Master of Special Education from Fairfield University.